Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: a systematic review
Kauark-Fontes E, Rodrigues-Oliveira L, Epstein JB, Faria KM, Araújo ALD, Gueiros LAM, Migliorati CA, Salloum RG, Burton P, Carroll J, Lopes MA, Alves CGB, Palmier NR, Prado-Ribeiro AC, Brandão TB, Santos-Silva AR
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 19 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Gobierno
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Gobierno
- Fundação de Amparo à Pesquisa do Estado de São Paulo (BR)
- Gobierno
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Subvenciones
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/23479‐3); Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/04657‐8); Fundação de Amparo à Pesquisa do Estado de São Paulo (18/02233-6)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2021-01-07 · Support Care Cancer · vol. 29 · número 6 · págs. 2875–2884
- Editorial
- Springer Science+Business Media
- Citado
- 32 citas · más que el 78% de estudios similares · 1.3× el promedio de su campo
- Referencias
- 41 trabajos
- Acceso
- Acceso abierto (copia en repositorio) · OTHER-OA
- Áreas de investigación
- Laser Applications in Dentistry and Medicine · Health Systems, Economic Evaluations, Quality of Life · Economic and Financial Impacts of Cancer
- Palabras clave
- low-level laser therapy, cost-effectiveness, cancer treatment toxicity, oral mucositis, breast cancer-related lymphedema, chemotherapy toxicity, radiotherapy toxicity, manual lymphatic drainage, physiotherapy
- MeSH
- humans, neoplasms, cost-benefit analysis, low-level light therapy
16 autores
- ELISA KAUARK FONTES🇧🇷Universidade Estadual de Campinas (UNICAMP)
- Letícia Rodrigues‐Oliveira🇧🇷Universidade Estadual de Campinas (UNICAMP)
- Joel Brian Epstein🇺🇸Cedars-Sinai Medical Center; City Of Hope National Medical Center
- Karina Morais Faria🇧🇷Instituto do Câncer do Estado de São Paulo
- Anna Luíza Damaceno Araújo🇧🇷Universidade Estadual de Campinas (UNICAMP)
- Luiz Alcino Gueiros🇧🇷Universidade Federal de Pernambuco
- Cesar Augusto Migliorati🇺🇸University of Florida
- Ramzi George Salloum🇺🇸University of Florida
- Patricia Burton
- James D. Carroll
- Márcio Ajudarte Lopes🇧🇷Universidade Estadual de Campinas (UNICAMP)
- Carolina Guimarães Bonfim Alves🇧🇷Universidade Estadual de Campinas (UNICAMP); Instituto do Câncer do Estado de São Paulo
- Natália Rangel Palmier🇧🇷Universidade Estadual de Campinas (UNICAMP)
- Ana Carolina Prado Ribeiro🇧🇷Universidade Estadual de Campinas (UNICAMP); Instituto do Câncer do Estado de São Paulo
- Thaís Bianca Brandão🇧🇷Instituto do Câncer do Estado de São Paulo
- Alan Roger Santos‐Silva🇧🇷 · autor de correspondenciaUniversidade Estadual de Campinas (UNICAMP)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To identify and summarize the evidence on the cost-effectiveness of photobiomodulation (PBM) therapy for the prevention and treatment of cancer treatment-related toxicities.
Methods
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE). Scopus, MEDLINE/PubMed, and Embase were searched electronically.
Results
A total of 1490 studies were identified, and after a two-step review, 4 articles met the inclusion criteria. The included studies analyzed the cost-effectiveness of PBM therapy used in the context of lymphedema for breast cancer and oral mucositis (OM) induced by chemotherapy and radiotherapy. Better outcomes were associated with PBM therapy. The incremental cost-effectiveness ratio ranged from 3050.75 USD to 5592.10 USD per grade 3-4 OM case prevented. PBM therapy cost 21.47 USD per percentage point reduction in lymphedema in comparison with 80.51 USD for manual lymph drainage and physical therapy.
Conclusion
There is limited evidence that PBM therapy is cost-effective in the prevention and treatment of specific cancer treatment-related toxicities, namely, OM and breast cancer-related lymphedema. Studies may have underreported the benefits due to a lack of a comprehensive cost evaluation. This suggests a wider acceptance of PBM therapy at cancer treatment centers, which has thus far been limited by the number of robust clinical studies that demonstrate cost-effectiveness for the prevention and treatment of toxicities.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.